Skip to content
Anthem Biosciences logo

Anthem Biosciences

ANTHEM NSE
₹888.30 +33.85 (+3.96%)
P/E
86.66
View as Markdown
MCP
Close 4 Nov 2026 ₹888.30 +191.70 +27.5% 1Y
Start ₹696.60

Key Fundamentals

MidcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
30.40%
Debt to Equity
0.02
EPS (TTM)
₹10.25
Book Value
₹54.01
Market Cap
—
P/E (TTM)
86.66
P/B
16.45
ROE
22.30%
Dividend Yield
0.23%
EBITDA
₹990 Cr
52W High
₹977.55
52W Low
₹579.15
Day Range
₹840.40 – ₹890.00
Volume
10,00,964

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

48 Average

Data confidence 100/100

Category scores

Quality
90
Strong
Returns, margins, earnings quality 22% weight
Valuation
26
Poor
Cheap vs sector & own history 24% weight
Growth
5
Poor
Sales & profit trajectory 9% weight
Financial Health
85
Strong
Solvency, leverage, coverage 9% weight
Momentum
39
Weak
Trend strength, vol-adjusted 12% weight
Ownership
36
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company's working capital requirements have reduced from 118 days to 92.3 days

Weaknesses

1
  • Stock is trading at 15.2 times its book value

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish2512
OscillatorsNeutral252
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
61.38
Neutral
MACD (12,26,9)
−6.54
Bullish
SMA (50)
880.78
Bullish
SMA (200)
769.90
Bullish

As of

Analyst Rating

Based on 8 analysts
BUY100%

8 of 8 analysts rate Buy, 0 Hold, 0 Sell.

As of

BUY
8
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+14.00%
3Y+26.19%
1Y+15.12%
TTM−2.15%

Net profit

Net profit growth by window
5Y+16.92%
3Y+15.42%
1Y+31.26%
TTM+14.06%

Operating cash flow

Operating cash flow growth by window
5Y+24.87%
3Y+40.24%
1Y+211.44%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y+2.28 pp
3Y−1.51 pp
1Y+2.85 pp
TTM+3.39 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2020₹633 Cr
Mar 2021₹1,103 Cr
Mar 2022₹1,231 Cr
Mar 2023₹1,057 Cr
Mar 2024₹1,419 Cr
Mar 2025₹1,845 Cr
Mar 2026₹2,124 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2020₹93.00 Cr
Mar 2021₹271 Cr
Mar 2022₹406 Cr
Mar 2023₹385 Cr
Mar 2024₹367 Cr
Mar 2025₹451 Cr
Mar 2026₹592 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹232 Cr −29.7% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 3 Nov 2026
AI opinion · based on fundamentals
Risk high

Anthem Biosciences Ltd trades at ₹854.45 as of 2026-11-03 with a market cap of ₹47,519.5 Cr. The company is virtually debt-free with a debt-to-equity ratio of 0.02 and has delivered a 3-year compounded profit growth of 21%, though its TTM sales growth has turned negative at -2% and the stock trades at a P/E of 83.36x, reflecting a rich valuation.

Bull Case 8
  • Near-zero leverage with a debt-to-equity ratio of just 0.02, providing significant financial flexibility and resilience through economic cycles
  • Strong 3-year compounded profit growth of 21% demonstrates consistent earnings expansion over a meaningful period
  • Healthy return ratios with ROE at 19.45% and ROCE at 26.78% as of 2026-11-03, indicating efficient capital deployment
  • 5-year average ROE of 23% shows the company has sustained high profitability over a longer horizon
  • Working capital efficiency has improved meaningfully, with requirements falling from 118 days to 92.3 days, freeing up cash for operations and growth
  • 5-year compounded profit growth of 17% indicates durable earnings momentum beyond just a cyclical uptick
  • Stock is trading roughly 12.6% below its 52-week high of ₹977.55, offering a more favourable entry relative to recent peak levels
  • The company has actively reduced debt, reinforcing balance sheet strength and lowering interest cost exposure
Bear Case 7
  • TTM sales growth has turned negative at -2%, signalling a potential revenue slowdown or demand headwind in the near term
  • P/E of 83.36x on TTM EPS of ₹10.25 prices the stock at a steep premium, leaving limited room for execution missteps
  • Price-to-book ratio of 15.82x is exceptionally high, meaning significant future growth is already embedded in the valuation
  • Dividend yield of just 0.24% offers negligible income return, making the investment thesis entirely dependent on capital appreciation
  • Despite 3-year compounded sales growth of 26%, the sharp deceleration to -2% TTM suggests the growth trajectory may be fading
  • TTM profit growth of 18% lags the 3-year CAGR of 21%, indicating a modest deceleration in earnings momentum as well
  • 1-year stock CAGR of 9% is modest relative to the elevated valuation multiples, suggesting the market may already be pricing in optimistic scenarios

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Anthem Biosciences shows strong price momentum with a 35% YTD gain and a 51% premium over its IPO price, but Q1 FY27 financials were weak with a 21% revenue decline and 12% PAT drop. A large block deal by Portsmouth Technologies added near-term supply pressure at a discount. The key risk is whether the revenue decline reverses in coming quarters; sustained earnings weakness could stall the stock's uptrend.

Headwinds 2
  • Q1 FY27 income drops 21% Oct 09

    Total income declined 21.3% YoY to ₹443.11 crore from ₹563.02 crore in Q1 FY27, while profit after tax fell 11.7% YoY to ₹119.94 crore and EPS dropped to ₹2.11 from ₹2.42.

  • Large stakeholder sells 30L shares Oct 09

    Portsmouth Technologies sold 30 lakh shares at ₹833 each (totaling ₹249.90 crore), roughly 19.49% of its holding, at a 3.29% discount to the closing price of ₹862.30.

Positives 2
  • Stock up 35% in 2026 Oct 09

    Anthem Biosciences has gained 34.80% YTD in 2026 and is up 19.72% over the last six months, with shares trading at a 51.11% premium over the IPO issue price of ₹570.

  • ₹48,564 crore market cap Oct 09

    The company's market cap stood at ₹48,564.31 crore at Friday's close of ₹862.30, well above its 52-week low of ₹579.15 hit on Feb 2, 2026.

Neutral 2
  • Block deal identity unknown Oct 09

    The buyer of the 30 lakh shares sold by Portsmouth Technologies was not immediately identified; Portsmouth's estimated residual holding stands at 1,23,96,327 shares (~2.20% stake).

  • Stock dips 1.17% on session Oct 09

    Shares closed at ₹862.30, down 1.17% from the previous close of ₹872.55, trading in a range of ₹842.20 to ₹880.20 during the session.

Quarterly Results

₹ Cr
ANTHEM quarterly results, ₹ crore
Particulars Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
339
525
498
483
540
550
423
611
418
594
Expenses
218
330
338
288
349
332
266
344
268
323
Operating Profit
121
195
160
195
191
218
157
267
151
271
OPM %
36%
37%
32%
40%
35%
40%
37%
44%
36%
46%
Other Income
19
28
24
14
23
48
8
51.21
25
59
Interest
4
4
3
1
2
3
0
2
1
3
Depreciation
19
20
20
30
26
34
35
40
30
31
PBT
118
200
161
178
186
230
130
278
145
296
Tax %
30%
19%
23%
54%
27%
24%
29%
32%
17%
29%
Net Profit
82
162
124
83
136
173
93
190
120
211
EPS (₹)
1.47
2.9
2.22
1.48
2.42
3.09
1.65
3.38
2.13
—

Sep 2026: from the results filed on 3 Nov 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
ANTHEM profit and loss, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
633
1,103
1,231
1,057
1,419
1,845
2,124
2,002
Expenses
451
695
666
626
914
1,173
1,290
1,209
Operating Profit
182
408
565
431
506
672
834
793
OPM %
29%
37%
46%
41%
36%
36%
39%
40%
Other Income
21
37
49
139
63
85
131
133
Interest
20
17
10
9
10
11
7
6
Depreciation
62
62
58
64
82
89
134
138
PBT
121
366
546
497
477
657
824
783
Tax %
23%
26%
26%
23%
23%
31%
28%
—
Net Profit
93
271
406
385
367
451
592
576
EPS (₹)
1.7
4.92
7.11
6.75
6.57
8.07
10.54
10.25
Div. Payout %
0%
0%
0%
0%
0%
0%
19%
—

Balance Sheet

₹ Cr
ANTHEM balance sheet, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
8
9
114
112
112
112
Reserves
413
693
1,346
1,627
1,813
2,298
2,930
Borrowings
159
100
35
126
239
113
54
Other Liabilities
207
232
228
148
235
284
333
Total Liabilities
787
1,034
1,619
2,014
2,398
2,808
3,429
Fixed Assets
306
361
329
449
483
705
783
CWIP
50
19
154
164
345
297
264
Investments
99
209
273
499
472
433
1,007
Other Assets
333
445
863
902
1,099
1,373
1,374
Total Assets
787
1,034
1,619
2,014
2,398
2,808
3,429

Cash Flow

₹ Cr
ANTHEM cash flow, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
166
278
333
306
140
271
844
Investing
−109
−196
−205
−376
−221
−147
−702
Financing
−48
−63
181
64
−77
−136
−40
Net Cash Flow
9
18
308
−6
−158
−12
103
Free Cash Flow
119
159
307
112
−156
12
637
CFO/EBITDA
116
85
81
98
51
64
126

Ratios

ANTHEM financial ratios, annual
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
61
84
97
95
126
89
101
Inventory Days
186
29
52
139
129
167
56
Days Payable
87
50
50
77
61
54
34
Cash Conversion Cycle
160
63
99
156
193
202
124
Working Capital Days
20
27
75
112
128
134
92
ROCE %
—
55%
51%
28%
24%
28%
30%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Anthem Biosciences insights

63 extracted metrics across FY20–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 71.40%
  • DIIs 12.10%
  • Public 9.47%
  • FIIs 3.79%
  • Others 3.24%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Anthem Biosciences

What does Anthem Biosciences Ltd do?
Incorporated in 2006, Anthem Biosciences Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.
Where is Anthem Biosciences Ltd (ANTHEM) listed?
Anthem Biosciences Ltd trades as ANTHEM on the NSE and under code 544449 on the BSE.
Which sector does Anthem Biosciences Ltd belong to?
Anthem Biosciences Ltd is classified under the Healthcare sector, in the Biotechnology industry.
What is the PE ratio of Anthem Biosciences Ltd?
Anthem Biosciences Ltd trades at a PE ratio of 86.66 as of 4 Nov 2026, on earnings per share of ₹10.25, against a book value of ₹54.01 per share.
What is the 52-week high and low of Anthem Biosciences Ltd?
Over the last 52 weeks Anthem Biosciences Ltd has traded between ₹579.15 and ₹977.55 as of 4 Nov 2026.
Does Anthem Biosciences Ltd pay dividends?
Anthem Biosciences Ltd has a dividend yield of 0.23%.
What is the Return on Equity (ROE) of Anthem Biosciences Ltd?
Anthem Biosciences Ltd reported a return on equity of 22.30%. Its debt-to-equity ratio is 0.02.

Company Information

Incorporated in 2006, Anthem Biosciences Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.

Website anthembio.com
CEO Mr. Ajay Bhardwaj B.Tech., M.S
Listed 21 Jul 2025
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ANTHEM.md for Anthem Biosciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month